Quarterly Updates14 Aug 2025, 05:52 pm
Glenmark Pharmaceuticals Announces Q1FY26 Results: India Business Grows by 3.7%, North America by 8.9% QoQ
AI Summary
Glenmark Pharmaceuticals Ltd. announced its financial results for the first quarter ended June 30, 2025. The company's consolidated revenue was Rs. 32,644 Mn, a 0.6% YoY increase. The India business grew by 3.7% YoY to Rs. 12,399 Mn, while the North America business grew by 8.9% QoQ to Rs. 7,780 Mn. The Europe business revenue was at Rs. 6,678 Mn, and the EBITDA was Rs. 5,805 Mn with an EBITDA margin of 17.8%. The Adjusted Profit After Tax (PAT) was Rs. 3,129 Mn with an adjusted PAT margin of 9.6%.
Key Highlights
- India Business grew by 3.7% YoY to Rs. 12,399 Mn
- North America Business grew by 8.9% QoQ to Rs. 7,780 Mn
- EBITDA of Rs. 5,805 Mn with an EBITDA margin of 17.8%
- Adjusted Profit After Tax (PAT) of Rs. 3,129 Mn with an adjusted PAT margin of 9.6%
- Glenmark’s Green House Gas (GHG) emission reduction targets have been approved by the Science Based Target initiative (SBTi)